razoxane has been researched along with Cardiotoxicity in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 3 (100.00) | 2.80 |
Authors | Studies |
---|---|
Armenian, SH; de Baat, EC; Feijen, EAM; Kremer, LCM; Mavinkurve-Groothuis, AMC; Mulder, RL; van Dalen, EC | 1 |
Bavlovič Piskáčková, H; Chládek, J; Jansová, H; Jirkovská, A; Karabanovich, G; Kollárová-Brázdová, P; Kubeš, J; Lenčová-Popelová, O; Melnikova, I; Roh, J; Šimůnek, T; Štěrba, M; Štěrbová-Kovaříková, P; Váňová, N | 1 |
Benjamin, RS; Minotti, G | 1 |
3 other study(ies) available for razoxane and Cardiotoxicity
Article | Year |
---|---|
Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Child; Dexrazoxane; Humans; Neoplasms; Polyketides; Razoxane | 2023 |
Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
Topics: Animals; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Diketopiperazines; DNA Topoisomerases, Type II; Male; Myocytes, Cardiac; Piperazine; Prodrugs; Rabbits; Razoxane; Topoisomerase II Inhibitors; Water | 2021 |
Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue Sarcomas: The Road to Cardioprotection.
Topics: Cardiotoxicity; Dexrazoxane; Doxorubicin; Humans; Razoxane; Sarcoma | 2021 |